VTechWorks staff will be away for the Thanksgiving holiday starting Wednesday afternoon, Nov. 25, through Sunday Nov. 29, and will not be replying to requests during this time. Thank you for your patience.

Show simple item record

dc.contributor.authorNeal, Robert E. IIen_US
dc.contributor.authorRossmeisl, John H. Jr.en_US
dc.contributor.authorRobertson, John L.en_US
dc.contributor.authorArena, Christopher B.en_US
dc.contributor.authorDavis, Erica M.en_US
dc.contributor.authorSingh, Ravi N.en_US
dc.contributor.authorStallings, Jonathanen_US
dc.contributor.authorDavalos, Rafael V.en_US
dc.date.accessioned2018-10-19T14:32:36Z
dc.date.available2018-10-19T14:32:36Z
dc.date.issued2013-05-24en_US
dc.identifier.othere64559en_US
dc.identifier.urihttp://hdl.handle.net/10919/85430
dc.description.abstractIrreversible electroporation (IRE) is a non-thermal focal ablation technique that uses a series of brief but intense electric pulses delivered into a targeted region of tissue, killing the cells by irrecoverably disrupting cellular membrane integrity. This study investigates if there is an improved local anti-tumor response in immunocompetent (IC) BALB/c versus immunodeficient (ID) nude mice, including the potential for a systemic protective effect against rechallenge. Subcutaneous murine renal carcinoma tumors were treated with an IRE pulsing protocol that used 60% of the predicted voltage required to invoke complete regressions in the ID mice. Tumors were followed for 34 days following treatment for 11 treated mice from each strain, and 7 controls from each strain. Mouse survival based on tumor burden and the progression-free disease period was substantially longer in the treated IC mice relative to the treated ID mice and sham controls for both strains. Treated IC mice were rechallenged with the same cell line 18 days after treatment, where growth of the second tumors was shown to be significantly reduced or prevented entirely. There was robust CD3+ cell infiltration in some treated BALB/C mice, with immunocytes focused at the transition between viable and dead tumor. There was no difference in the low immunocyte presence for untreated tumors, nude mice, and matrigel-only injections in both strains. These findings suggest IRE therapy may have greater therapeutic efficacy in immunocompetent patients than what has been suggested by immunodeficient models, and that IRE may invoke a systemic response beyond the targeted ablation region.en_US
dc.format.mimetypeapplication/pdfen_US
dc.language.isoen_USen_US
dc.publisherPLOSen_US
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleImproved Local and Systemic Anti-Tumor Efficacy for Irreversible Electroporation in Immunocompetent versus Immunodeficient Miceen_US
dc.typeArticle - Refereeden_US
dc.description.versionPeer Revieweden_US
dc.contributor.departmentComparative Oncology Research Center (CORC)en_US
dc.contributor.departmentSmall Animal Clinical Sciencesen_US
dc.contributor.departmentSchool of Biomedical Engineering and Sciencesen_US
dc.title.serialPLOS ONEen_US
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0064559en_US
dc.identifier.volume8en_US
dc.identifier.issue5en_US
dc.type.dcmitypeTexten_US
dc.identifier.pmid23717630en_US
dc.identifier.eissn1932-6203en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International
License: Creative Commons Attribution 4.0 International